Pardes Biosciences (PRDS) Stock Analysis

What Pardes Biosciences does

Pardes Biosciences, Inc. is a clinical-stage biopharmaceutical firm dedicated to identifying, developing, and marketing groundbreaking treatments. The company's core objective is to improve outcomes for patients battling life-threatening illnesses. Its primary investigational therapy, PBI-0451, is currently progressing through clinical development with the aim of both treating and preventing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections and their related health issues. Established in 2020, Pardes Biosciences maintains its corporate headquarters in Carlsbad, California.

Key metrics

ETFs linked to PRDS

Broad-market and Healthcare sector ETFs an investor holding Pardes Biosciences is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how PRDS fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Pardes Biosciences?

Pardes Biosciences trades under the ticker PRDS on NASDAQ.

Which exchange is PRDS listed on?

PRDS is listed on NASDAQ.

What sector does Pardes Biosciences operate in?

Pardes Biosciences is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze PRDS in a portfolio?

PortView shows PRDS's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.